There are a handful of different factors that could buoy its stock. As its shareholders already know, CRISPR Therapeutics (CRSP -0.88%) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint blockbuster drugs, and plenty of financial flexibility, there's no shortage of reasons to buy the stock. But even for those who appreciate the company's merits, the picture is likely even sunnier than they realize. Here are three reasons why the sto ...